Sabine Grüschow Selected Research

Infections

3/2024	CRISPR antiphage defence mediated by the cyclic nucleotide-binding membrane protein Csx23.
1/2022	Cyclic nucleotide-induced helical structure activates a TIR immune effector.
1/2021	The CRISPR ancillary effector Can2 is a dual-specificity nuclease potentiating type III CRISPR defence.
1/2020	The dynamic interplay of host and viral enzymes in type III CRISPR-mediated cyclic nucleotide signalling.
1/2020	Tetramerisation of the CRISPR ring nuclease Crn3/Csx3 facilitates cyclic oligoadenylate cleavage.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sabine Grüschow Research Topics

Disease

5	Infections 03/2024 - 01/2020
2	Virus Diseases (Viral Diseases) 01/2020 - 12/2019
1	Tuberculosis (Tuberculoses) 01/2019
1	Mycoses (Diseases, Fungus) 01/2012
1	Dehydration (Water Stress) 10/2011
1	Neoplasms (Cancer) 05/2007

Drug/Important Bio-Agent (IBA)

3	RNA (Ribonucleic Acid)IBA 03/2024 - 01/2020
3	Coenzyme A (CoA)IBA 01/2020 - 12/2019
3	2',5'-oligoadenylate (PAPAPA)IBA 01/2020 - 12/2019
2	Ribonucleases (Ribonuclease)IBA 01/2021 - 12/2019
1	NucleotidesIBA 03/2024
1	Interleukin-1 Receptors (Interleukin 1 Receptor)IBA 01/2022
1	cyclic tetra-adenylateIBA 01/2021
1	Deoxyribonucleases (DNase)FDA Link 01/2021
1	Cyclic NucleotidesIBA 01/2020
1	EnzymesIBA 01/2020
1	Nucleic AcidsIBA 01/2020
1	OligonucleotidesIBA 01/2019
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2012
1	AldehydesIBA 10/2011
1	Mitomycin (Mitomycin-C)FDA LinkGeneric 05/2007

Therapy/Procedure

1	Therapeutics 05/2007